Visoluten
A natural-extract eye-tissue polypeptide preparation sold in Russia as a dietary supplement in the Khavinson consumer “Cytomax” line, marketed for retinal support. There is no published study of Visoluten itself. A PubMed search for the product name, in either common transliteration, returns zero records, and the two papers usually cited for it are about other members of the same catalogue: Trofimova and Khavinson (2001) treated 104 patients with diabetic retinopathy using retinalamine, epithalamine and cortexine, and the 2014 Khavinson paper discusses peptide bioregulators generically in retinitis pigmentosa without naming any product. Neither mentions Visoluten, with the broader Khavinson framework's mechanistic and evidence limitations applying.
Visoluten is the clearest case in this atlas of a product whose evidence belongs to something else. It is an oral capsule of polypeptides extracted from cattle eye tissue, sold in Russia as a dietary supplement — not, as is frequently claimed and as this page itself used to say in four places, a registered medicine. No study of Visoluten has ever been published, in any language. Searches for the name in all three transliterations return nothing in PubMed and nothing in Europe PMC, and the Russian open-access literature does not contain it either, while the same search for Retinalamin returns 186 articles. That contrast is the whole story. Retinalamin is a different product: a registered Russian prescription medicine from Geropharm, a 5 mg lyophilisate of cattle retinal polypeptides given by intramuscular or parabulbar injection, with real indications and a real clinical literature including work from groups with no connection to the Khavinson school. The diabetic retinopathy and retinitis pigmentosa results attached to Visoluten in vendor copy are Retinalamin's, and the two papers usually cited for Visoluten studied retinalamine, epithalamine and cortexine, or named no product at all. The Khavinson school's own synthetic retina peptide is a third thing again, the tetrapeptide Epitalon. Anyone with retinal disease should be in the hands of an ophthalmologist, where anti-VEGF injection, laser and gene therapy have evidence that none of this does.
What is Visoluten?
Visoluten is a natural-extract polypeptide preparation from the Khavinson catalog, derived from animal retinal tissue and positioned for retinal disorders including diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration, and other retinal dystrophies. The molecule belongs to the consumer “Cytomax” line of oral capsules, not to the registered cytomedin medicines of the Khavinson program. That distinction matters and the marketing elides it: the cytomedin drugs developed at the Military Medical Academy — Thymalin (thymus), Epithalamin (pineal), Cortexin (cerebral cortex), Prostatilen (prostate) and, for the eye, Retinalamin — are injectable prescription preparations with registration dossiers behind them. Visoluten is not among them. Khavinson's own reviews enumerate the school's preparations without listing it. The Trofimova 2001 Vestnik Oftalmologii paper (PMID 11521426) and Khavinson's 2014 Fiziologiia Cheloveka paper (PMID 25272779) are the two citations usually attached to Visoluten, and neither studied it — the first tested retinalamine, epithalamine and cortexine, the second names no product at all. They are class context, not an evidence base. As with other Khavinson natural-extract preparations, Visoluten is sold in Russia as a dietary supplement rather than a registered medicine — the registered Russian retinal medicine is a different product, Retinalamin — and it is not FDA-approved or registered in any major Western jurisdiction. The peptide is sold through some Western research-channel sources for laboratory use and through Russian-market dietary peptide complex channels (Peptides.ru, Khavinson Peptides product line). The broader Khavinson framework limitations apply — the mechanistic claims of tissue-specific peptide-DNA-binding gene regulation have not been validated to mainstream Western molecular biology standards, and the in-vivo pharmacology of the natural-extract preparation specifically is not characterized in PubMed-indexed Western literature beyond the Russian clinical reports.
What Visoluten Is Investigated For
Visoluten is a Russian-tradition Khavinson bioregulator topic, not a Western clinical ophthalmology therapy. The oral natural-extract capsule is marketed for diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration and other retinal dystrophies under the Khavinson framework, but the marketing is doing all the work: no study of Visoluten has been published in any language. The Trofimova 2001 (PMID 11521426) and Khavinson 2014 (PMID 25272779) papers usually offered as its evidence tested other preparations or named none, and the injectable product that genuinely carries the Russian ophthalmology literature for these indications is Retinalamin. The molecule has not been FDA-approved, EMA-approved, or registered in any major Western jurisdiction, and the Khavinson framework's broader mechanistic claims (tissue-specific peptide-DNA binding with selective gene regulation) have not been validated to mainstream Western molecular biology standards. Anyone with diagnosed retinal disease should engage with Western ophthalmology — anti-VEGF biologics (aflibercept, ranibizumab, faricimab for diabetic macular edema and wet AMD), VEGF receptor inhibitors, gene therapy where applicable (voretigene neparvovec for RPE65-mediated retinitis pigmentosa), laser interventions, and other validated retinal-disease treatments — rather than research-channel Khavinson natural extracts.
How It Works
Visoluten is a natural extract from animal retinal tissue used in Russian eye medicine for things like diabetic retinopathy and retinitis pigmentosa. It's part of the Khavinson family of tissue-specific peptide preparations — the idea being that a peptide extract from retinal tissue helps support retinal function. The Russian clinical experience exists but is poorly indexed in Western databases, and the broader Khavinson mechanism story (peptides selectively turning genes on or off in their target tissues) hasn't been validated to mainstream Western molecular biology standards. For anyone with actual retinal disease, modern Western ophthalmology (anti-VEGF injections, gene therapy where applicable, glycemic control for diabetic retinopathy) should be the foundation rather than research-channel natural extracts.
Visoluten is positioned within the Khavinson natural-extract bioregulator framework as a retinal-tissue-targeted polypeptide preparation. The proposed mechanism follows the broader Khavinson hypothesis that small peptides act as tissue-specific epigenetic regulators, binding directly to DNA in target tissues and modulating gene expression in tissue-typical patterns. For Visoluten specifically, the proposed application is supporting retinal function in diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration, and other retinal dystrophic conditions — through gene-expression modulation in retinal cells (photoreceptors, retinal pigment epithelium, vascular endothelium) that supports cellular function and slows degenerative progression. The mechanistic case is at the cosmetic-and-tradition framework level rather than at the molecular biology rigorous level. The Khavinson framework's broader limitations — short peptides with rapid plasma degradation and poor oral bioavailability, facing the blood-retinal barrier rather than reaching the retina freely, proposed direct peptide-DNA binding without structural-biology validation, predominantly Russian-language literature without independent Western replication — all apply specifically to Visoluten. There is no published evidence for Visoluten specifically in any indexed source. The Trofimova 2001 (PMID 11521426) and Khavinson 2014 (PMID 25272779) Russian-language papers are cited for class context only, and the mechanistic work that does exist in this area was done on other preparations. A 2003 study from Khavinson's own group (PMID 12937684) tested the proliferative effects of two agents on retinal and pigmented epithelial cells, and names them precisely: Retinalamin, the polypeptide preparation isolated from retina, and the synthetic tetrapeptide Epitalon. Khavinson's 2002 English-language review of the framework (PMID 12374906) says the same thing from the other direction — the peptide designed for the retina is Ala-Glu-Asp-Gly, shared with the pineal gland on the reasoning that the two organs have a common embryonal origin, and the eye-retina preparation with clinical trials behind it is the extract that became Retinalamin. Neither paper mentions Visoluten. There is also now in vitro work from outside the originating group: a 2019 study from the Research Institute of Eye Diseases and Sechenov University, with no Khavinson co-author, found the cattle-retina bioregulator non-cytotoxic to cultured retinal cells and able to reduce glutamate toxicity in a model of glaucomatous optic neuropathy (PMID 30830079). That is a genuinely independent result — and it is about Retinalamin.
Evidence Snapshot
Human Clinical Evidence
None. This is the most important fact about Visoluten and it is easy to miss: there is no published clinical study of this product in any language. A PubMed search for the product name, in either transliteration, returns zero records, and the same search returns nothing in Europe PMC or in the main Russian open-access aggregator. That is not a case of Russian work being poorly indexed in Western databases — the Russian literature does not contain it either. The two papers usually cited alongside Visoluten studied other preparations from the same catalogue, chiefly retinalamine. Any efficacy claim made for Visoluten specifically traces to marketing material, not to a study.
Animal / Preclinical
None specific to Visoluten. The broader Khavinson framework offers general mechanistic claims about short peptides regulating gene expression, which have not been independently replicated outside the originating group.
Mechanistic Rationale
Speculative. Standard Khavinson framework limitations apply.
Research Gaps & Open Questions
What the current literature has not yet settled about Visoluten:
- 01Western controlled clinical trials of Visoluten in retinal disease
- 02Mechanism characterization at the molecular biology level for retinal-cell effects
- 03Comparative effectiveness vs validated retinal disease treatments (anti-VEGF, gene therapy where applicable)
Forms & Administration
Visoluten is sold as a Russian-market dietary peptide complex (Peptides.ru, Khavinson Peptides product line) and through some Western research-channel sources for laboratory use. It is a supplement rather than a registered medicine in Russia, supplied as oral capsules and tablets; the injectable retinal preparation used clinically there is Retinalamin, a different product. There is no FDA-approved formulation.
Common Questions
What is Visoluten?
Visoluten is a natural-extract polypeptide preparation derived from animal retinal tissue, part of the Khavinson catalog of Russian tradition tissue-specific bioregulators. It is positioned for retinal disorders including diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration, and other retinal dystrophies. It is sold in Russia as a dietary supplement rather than as a registered medicine, and it is not FDA-approved or registered in any major Western jurisdiction. The product with an actual ophthalmology practice behind it is Retinalamin — a different, injectable, prescription preparation from a different manufacturer, whose clinical use is routinely transferred onto Visoluten in vendor copy. The registered Russian medicine for retinal indications is Retinalamin, a different product from a different manufacturer; the two are frequently conflated.
How is Visoluten different from Vesilute?
Both are Khavinson catalog entries with similar-sounding names but different tissue targets. Visoluten is a natural eye-tissue extract sold as an oral supplement. Vesilute is something quite different: a synthetic dipeptide, Glu-Asp, marketed as a bladder bioregulator. The name that actually belongs to the vascular slot is Vesugen, the Lys-Glu-Asp tripeptide — Vesilute and Vesugen are the pair most often mixed up, and vendor copy mixes them up constantly. So the honest answer is that Visoluten and Vesilute share a naming convention and a catalogue, and nothing else: different tissue, different chemistry, different product type.
Should I use Visoluten for diabetic retinopathy or retinitis pigmentosa?
No — engage with Western ophthalmology instead. Diabetic retinopathy is treated with glycemic control optimization, blood pressure management, anti-VEGF intravitreal injections (aflibercept, ranibizumab, faricimab), focal/grid laser, vitrectomy in advanced cases, and other validated interventions. Retinitis pigmentosa management includes vitamin A palmitate supplementation in select genotypes, voretigene neparvovec gene therapy for RPE65-mediated disease, retinal prosthesis where applicable (Argus II historically; newer technologies in development), low-vision rehabilitation, and emerging gene therapy approaches. Visoluten is a research-tier Russian-tradition adjunct rather than a substitute for any of these.
Who Visoluten Is NOT For
- •Individual intolerance of the components — the only contraindication the Russian supplement listing itself states, alongside pregnancy and breastfeeding
- •Patients with retinal disease requiring Western ophthalmology evaluation — Visoluten is not a substitute for validated treatment
- •Pregnancy and lactation — no safety data
- •Pediatric populations — limited data
- •Patients on biologic anti-VEGF therapy or other ophthalmology drug classes — interaction is uncharacterized
Drug & Supplement Interactions
No validated human drug-interaction profile. Theoretical concerns about interactions with biologic anti-VEGF therapy or other retinal disease treatments are uncharacterized.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved — not registered as a prescription medicine in any major Western jurisdiction
- • Russian-tradition framework with mechanistic claims not validated to Western molecular biology standards
- • Retinal disease patients should engage with Western ophthalmology rather than relying on research-channel natural extracts
- • Quality control varies across Russian-market and Western research-channel sources
What We Don't Know
Long-term safety, pharmacokinetics, and clinical effects of Visoluten in Western practice are not characterized. The Khavinson framework's broader limitations — mechanistic speculation, limited Western evidence base, registry-medication-vs-research-tier ambiguity — apply.
Legal Status
United States
Visoluten is not FDA-approved for any indication. It is sold as a dietary supplement or research peptide rather than a prescription medicine.
International
Visoluten is sold in Russia as a dietary supplement (БАД), not as a registered medicine. The Russian drug reference RLS lists Визолутен under supplements — 0.2 g capsules and 0.3 g tablets, described only as an additional source of peptides — rather than under medicines. The registered Russian retinal medicine is Retinalamin (Geropharm), a 5 mg lyophilisate of cattle retinal polypeptides for intramuscular or parabulbar injection, which is a different product with a different route, manufacturer and regulatory status. Visoluten is not registered as a medicine in any Western market.
Sports & Competition
Not specifically named on the WADA Prohibited List.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Visoluten cures retinal disease.
Reality
It does not. There is no rigorous evidence supporting cure or substantial disease modification claims for retinal disease with Visoluten. Modern Western ophthalmology offers validated treatments (anti-VEGF, gene therapy in select cases, glycemic control for diabetic retinopathy) that should be the foundation of retinal disease care.
Myth
Visoluten is FDA-approved for retinitis pigmentosa or diabetic retinopathy.
Reality
It is not, and the premise is wrong twice over. Visoluten does not hold medication registration in Russia either — it is sold there as a dietary supplement, and the registered Russian retinal medicine is Retinalamin, a different injectable product from a different manufacturer. Nothing called Visoluten is approved as a medicine anywhere.
Published Research
5 studies[Evaluation of therapeutic sensitivity of retinal ganglion cells to targeted peptide bioregulator in culture].
[Molecular-physiological aspects of peptide regulation of function of the retina in retinitis pigmentosa]
Khavinson and colleagues, Fiziologiia Cheloveka 2014 (Russian-language). A short review of peptide regulation of retinal function in retinitis pigmentosa. It names no specific product, Visoluten included, and is cited here only as background on the Khavinson group's general framework.
Effects of peptides on proliferative activity of retinal and pigmented epithelial cells.
Peptides and Ageing.
[Effectiveness of bio-regulators in the treatment of diabetic retinopathy]
Trofimova and Khavinson, Vestnik Oftalmologii 2001 (Russian-language). Cited here for class context only: the products studied were retinalamine, epithalamine and cortexine, given to 104 patients with diabetic retinopathy against 42 controls. Visoluten is not among them and is not mentioned in the paper.
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 5PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.